Clinical trial
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With…
NCT00058279 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00058279 |
|---|---|
| Title | Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma |
| Official title | MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, ipilimumab |
| Start date | Feb 1, 2003 |
| Completion | Aug 1, 2006 |
| First posted | Apr 9, 2003 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: